Veradermics (MANE) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.50

Estimate

-$0.62

Surprise

+18.8%

Score today

4.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Veradermics (MANE) reported a narrower loss than forecast — adjusted EPS of -$0.50 against the -$0.62 estimate (a 18.8% beat on a still-unprofitable quarter).

• Citigroup Maintains Buy on Veradermics, Raises Price Target to $175 — benzinga, 2026-11-10
• Veradermics Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-10
• Leerink Partners Maintains Outperform on Veradermics, Raises Price Target to $150 — benzinga, 2026-11-09

TrendMatrix currently rates MANE Sell at 4.9/10; no pre/post engine snapshot brackets this report.

1 of the last 3 quarters beat the estimate; this quarter's +18.8% surprise compares with a -227.2% four-quarter average. Next scheduled report: 2027-03-29.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$156.56

Stop

$145.60

Model outputs from TrendMatrix’s engine as of 2026-11-12 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$6.54B

P/E (fwd)

-60.2

52-week range

$32.00–$156.60

Off 52-week high

0.0%

RSI (14)

64

Volume vs avg

1.11×

Score today

4.9/10